Certara Executive and Leadership Team

William Feehery, the Chief Executive Officer at Certara, directs the company's overall strategy and operational execution. Feehery guides Certara's mission to accelerate the development of life-changing medicines by leveraging advanced software, AI platforms, and scientific consulting. Overseeing the integration of model-informed drug development (MIDD) and biosimulation technologies, Feehery ensures these tools effectively predict drug behavior and optimize clinical outcomes. This leadership involves fostering innovation across all business units, driving growth, and maintaining Certara's position as a leader in scientific services. The Chief Executive Officer's purview extends to shaping the company's market impact and ensuring alignment with the evolving needs of the pharmaceutical and biotechnology industries. William Feehery's strategic vision propels the organization forward, focusing on enhancing efficiency and success rates in drug development for clients worldwide.

Faiz Mohammed, the Interim Chief Financial Officer. at Certara, manages the company's financial operations and strategic fiscal planning. Mohammed oversees all aspects of financial reporting, budgeting, and resource allocation, ensuring the fiscal health and sustainability of Certara's diverse service offerings. This role is critical in supporting the company's mission to accelerate drug development through advanced software, AI platforms, and scientific consulting. The Interim Chief Financial Officer. works closely with executive leadership to drive financial performance and optimize investment in key areas like model-informed drug development (MIDD) and biosimulation technologies. Faiz Mohammed's expertise guides financial decision-making, supporting Certara's growth initiatives and its commitment to delivering value to stakeholders and clients in the global pharmaceutical and biotechnology markets.

Adrian McKemey, the President, Certara Drug Development Solutions at Certara, directs the strategic growth and operational excellence of the company's core drug development services. McKemey oversees the delivery of integrated solutions that span the entire drug lifecycle, from discovery through regulatory approval and market access. This leadership focuses on leveraging Certara's expertise in model-informed drug development (MIDD) and biosimulation technologies to help clients optimize clinical outcomes and accelerate therapeutic innovation. The President, Certara Drug Development Solutions drives the expansion of services that support complex regulatory submissions and market access strategies. Adrian McKemey's commitment is to ensure clients receive unparalleled scientific support and advanced technological tools, reinforcing Certara's position as a vital partner in bringing life-changing medicines to patients globally.

Leif Pedersen, the President & Chief Commercial Officer at Certara, leads the global commercial strategy and revenue generation for the company's comprehensive suite of solutions. Pedersen drives market penetration and customer acquisition across Certara's software, AI platforms, and scientific consulting services. This role is pivotal in communicating the value proposition of model-informed drug development (MIDD) and biosimulation technologies to pharmaceutical and biotechnology clients worldwide. The President & Chief Commercial Officer oversees sales, business development, and customer success functions, ensuring alignment with market needs and company growth objectives. Leif Pedersen's leadership focuses on expanding Certara's reach and impact, fostering strong client relationships, and solidifying the company's role in accelerating the delivery of innovative medicines to patients.

Martin Snyder, the President, Certara Data Sciences at Certara, directs the strategic development and application of advanced data analytics and AI within the drug development process. Snyder oversees the teams responsible for generating insights from complex datasets, enhancing the predictive power of model-informed drug development (MIDD) and biosimulation technologies. This leadership ensures Certara's data science capabilities effectively support clients in optimizing clinical trial design, predicting drug efficacy, and navigating regulatory pathways. The President, Certara Data Sciences drives innovation in data integration and analysis, providing clients with actionable intelligence to accelerate the journey of new medicines from discovery to market. Martin Snyder's focus is on leveraging data to unlock new possibilities in pharmaceutical research and development, reinforcing Certara's commitment to scientific advancement.

Sheila Rocchio, the Chief Marketing Officer at Certara, architects and executes the company's global marketing strategies. Rocchio drives brand awareness and market positioning for Certara's comprehensive suite of software, AI-driven platforms, and scientific consulting services. This role involves translating the value of model-informed drug development (MIDD) and biosimulation technologies to diverse audiences within the pharmaceutical and biotechnology sectors. Overseeing all marketing initiatives, Sheila Rocchio ensures consistent messaging that highlights Certara's impact on accelerating drug discovery and optimizing clinical outcomes. The Chief Marketing Officer's responsibilities include market analysis, lead generation, and cultivating strong customer relationships. By championing Certara's scientific expertise, Rocchio directly supports the company's commercial objectives and reinforces its leadership in the drug development lifecycle.

Chris Bouton, the Chief Technology Officer at Certara, spearheads the technological vision and innovation across the company's software and AI-driven platforms. Bouton directs the development and enhancement of solutions that support the entire drug development lifecycle, from discovery to market access. This leadership involves ensuring Certara's technology stack effectively integrates model-informed drug development (MIDD) and biosimulation capabilities, enabling precise prediction of drug behavior and optimization of clinical outcomes. The Chief Technology Officer oversees research and development, driving advancements in AI and data science to deliver cutting-edge tools to clients. Chris Bouton's focus is on building scalable, robust technological infrastructure that empowers scientific breakthroughs and enhances operational efficiency for Certara's partners in the pharmaceutical and biotechnology industries.

Rona Anhalt, the Chief Human Resources Officer at Certara, leads the strategic development and execution of human capital initiatives. Anhalt cultivates a high-performance culture that supports Certara's mission of accelerating drug development through its advanced platforms and scientific expertise. This role involves attracting, developing, and retaining top talent across all functions, including software engineering, AI research, and scientific consulting. The Chief Human Resources Officer ensures that Certara's workforce is equipped with the skills necessary to drive innovation in model-informed drug development (MIDD) and biosimulation technologies. Rona Anhalt's leadership focuses on fostering employee engagement, promoting diversity and inclusion, and aligning HR strategies with the company's overall business objectives, thereby strengthening Certara's capacity to serve the pharmaceutical and biotechnology industries effectively.